DK1327440T5 - Orale pr parater med gunstige nedbrydningsegenskaber - Google Patents
Orale pr parater med gunstige nedbrydningsegenskaberInfo
- Publication number
- DK1327440T5 DK1327440T5 DK01965637T DK01965637T DK1327440T5 DK 1327440 T5 DK1327440 T5 DK 1327440T5 DK 01965637 T DK01965637 T DK 01965637T DK 01965637 T DK01965637 T DK 01965637T DK 1327440 T5 DK1327440 T5 DK 1327440T5
- Authority
- DK
- Denmark
- Prior art keywords
- water
- carmellose
- sodium
- disintegrant
- granule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000288234 | 2000-09-22 | ||
PCT/JP2001/007983 WO2002024166A1 (fr) | 2000-09-22 | 2001-09-14 | Preparations orales dotees de bonnes caracteristiques de desagregation |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1327440T3 DK1327440T3 (da) | 2009-06-08 |
DK1327440T5 true DK1327440T5 (da) | 2009-09-07 |
Family
ID=18771855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01965637T DK1327440T5 (da) | 2000-09-22 | 2001-09-14 | Orale pr parater med gunstige nedbrydningsegenskaber |
Country Status (11)
Country | Link |
---|---|
US (1) | US7727553B2 (de) |
EP (2) | EP1327440B1 (de) |
JP (1) | JP4868695B2 (de) |
AT (1) | ATE431136T1 (de) |
AU (1) | AU2001286237A1 (de) |
CA (2) | CA2824077C (de) |
DE (1) | DE60138722D1 (de) |
DK (1) | DK1327440T5 (de) |
ES (1) | ES2325764T3 (de) |
TW (2) | TWI289063B (de) |
WO (1) | WO2002024166A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017973A1 (ja) | 2002-08-22 | 2004-03-04 | Sumitomo Pharmaceuticals Company, Limited | 統合失調症治療剤 |
SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
EP1637530A4 (de) | 2003-06-23 | 2009-04-01 | Dainippon Sumitomo Pharma Co | Therapeutisches mittel für senile demenz |
EP2357474A1 (de) | 2004-02-20 | 2011-08-17 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidon zur Verwendung in der Behandlung von Gedächtnis- oder Lernstörungen bei Schizophrenie |
US8980316B2 (en) * | 2005-05-18 | 2015-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Stable tablet containing droxidopa |
ES2535478T3 (es) | 2005-05-26 | 2015-05-12 | Sumitomo Dainippon Pharma Co., Ltd. | Composición farmacéutica |
CN101198331B (zh) | 2005-06-13 | 2012-05-02 | 大日本住友制药株式会社 | 增溶化制剂 |
WO2007018190A1 (ja) * | 2005-08-10 | 2007-02-15 | Shionogi & Co., Ltd. | 苦味抑制製剤 |
KR101465803B1 (ko) * | 2005-08-10 | 2014-11-26 | 시오노기세이야쿠가부시키가이샤 | 구강내 붕괴 정제 |
EP1973531A2 (de) * | 2006-01-02 | 2008-10-01 | Rubicon Research Private Limited | Pharmazeutische zusammensetzungen |
AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
BRPI0819231B8 (pt) | 2007-10-31 | 2021-05-25 | Mcneil Ppc Inc | processo para preparo de forma farmacêutica de desintegração rápida por moldagem a quente na presença de sal inorgânico hidratado |
EP2251012A4 (de) | 2008-02-11 | 2013-03-06 | Dainippon Sumitomo Pharma Co | Tablette mit verbesserten elutionseigenschaften |
ES2400774T3 (es) | 2008-06-13 | 2013-04-12 | Dainippon Sumitomo Pharma Co., Ltd. | Tableta que se disgrega rápidamente en la cavidad oral y método para producción de la misma |
ES2855426T3 (es) * | 2008-09-17 | 2021-09-23 | Mylan Inc | Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen |
US20110318411A1 (en) | 2010-06-24 | 2011-12-29 | Luber Joseph R | Multi-layered orally disintegrating tablet and the manufacture thereof |
US8343533B2 (en) | 2009-09-24 | 2013-01-01 | Mcneil-Ppc, Inc. | Manufacture of lozenge product with radiofrequency |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
WO2012107890A2 (en) * | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
US9433620B2 (en) * | 2011-05-13 | 2016-09-06 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
JP6275109B2 (ja) | 2012-03-21 | 2018-02-07 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Ecg信号に基づいて睡眠の質の視覚的表現を提供するための方法及び装置 |
US9511028B2 (en) * | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
JP6007169B2 (ja) * | 2012-11-30 | 2016-10-12 | 大原薬品工業株式会社 | アリピプラゾール無水物を含有する固形製剤の製造方法 |
WO2014090386A1 (en) | 2012-12-11 | 2014-06-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Orally disintegrating tablet containing asenapine |
JP6037824B2 (ja) * | 2012-12-28 | 2016-12-07 | ライオン株式会社 | エトドラク含有固形製剤 |
JP2014129238A (ja) * | 2012-12-28 | 2014-07-10 | Lion Corp | エトドラク含有固形製剤 |
JP6505721B2 (ja) | 2014-01-10 | 2019-04-24 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッド | 高周波及び損失性被覆粒子を使用した錠剤の製造プロセス |
WO2016012898A1 (en) | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
WO2016139683A2 (en) * | 2015-03-05 | 2016-09-09 | Jubilant Generics Limited | Pharmaceutical compositions of lurasidone and process for preparing the same |
US10966928B2 (en) | 2016-03-25 | 2021-04-06 | Universiteit Gent | Oral dosage form |
BR112018069440A2 (pt) | 2016-03-25 | 2019-02-12 | Univ Gent | forma de dosagem oral |
TW201735928A (zh) * | 2016-03-31 | 2017-10-16 | 大日本住友製藥股份有限公司 | 溶出性優異之口服製劑 |
WO2018043613A1 (ja) * | 2016-08-31 | 2018-03-08 | 大日本住友製薬株式会社 | 水性懸濁型製剤 |
WO2018130943A1 (en) | 2017-01-11 | 2018-07-19 | Piramal Enterprises Limited | Oral pharmaceutical composition of lurasidone and preparation thereof |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
AT17300U3 (de) * | 2020-12-03 | 2022-02-15 | G L Pharma Gmbh | Feste orale pharmazeutische Zusammensetzung |
TW202333719A (zh) * | 2021-11-04 | 2023-09-01 | 大陸商上海博志研新藥物技術有限公司 | 鹽酸魯拉西酮口溶膜組合物、其製備方法及用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61148114A (ja) | 1984-11-15 | 1986-07-05 | Teijin Ltd | ニフエジピンの顆粒剤 |
JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
JPH04305526A (ja) * | 1991-03-28 | 1992-10-28 | Morishita Roussel Kk | 薬剤組成物 |
ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5811120A (en) * | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
EP0839526A3 (de) * | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften |
TW482675B (en) | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
BR9813808A (pt) | 1997-12-19 | 2002-05-28 | Smithkline Beecham Corp | Processo para produção de comprimidos para dispersão na mordida |
US6465009B1 (en) | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
JP4438121B2 (ja) | 1998-04-27 | 2010-03-24 | 大正製薬株式会社 | 口腔内速崩錠及びその製造方法 |
KR100267576B1 (ko) * | 1998-07-25 | 2000-11-01 | 허계성 | 활성성분을 분리함유한 츄잉 연질정제 및 그의 제조방법 |
JP2000086503A (ja) | 1998-09-07 | 2000-03-28 | Pola Chem Ind Inc | 錠剤医薬組成物 |
JP2000086509A (ja) | 1998-09-14 | 2000-03-28 | Taisho Yakuhin Kogyo Kk | ソファルコン含有製剤の製造方法 |
US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
-
2001
- 2001-09-14 DE DE60138722T patent/DE60138722D1/de not_active Expired - Lifetime
- 2001-09-14 AT AT01965637T patent/ATE431136T1/de not_active IP Right Cessation
- 2001-09-14 US US10/381,036 patent/US7727553B2/en not_active Expired - Lifetime
- 2001-09-14 EP EP01965637A patent/EP1327440B1/de not_active Expired - Lifetime
- 2001-09-14 CA CA2824077A patent/CA2824077C/en not_active Expired - Lifetime
- 2001-09-14 ES ES01965637T patent/ES2325764T3/es not_active Expired - Lifetime
- 2001-09-14 EP EP08156778A patent/EP1974724A3/de not_active Withdrawn
- 2001-09-14 DK DK01965637T patent/DK1327440T5/da active
- 2001-09-14 AU AU2001286237A patent/AU2001286237A1/en not_active Abandoned
- 2001-09-14 JP JP2002528202A patent/JP4868695B2/ja not_active Expired - Fee Related
- 2001-09-14 WO PCT/JP2001/007983 patent/WO2002024166A1/ja active Application Filing
- 2001-09-14 CA CA2424001A patent/CA2424001C/en not_active Expired - Lifetime
- 2001-09-19 TW TW094103731A patent/TWI289063B/zh not_active IP Right Cessation
- 2001-09-19 TW TW090123036A patent/TWI289062B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TWI289062B (en) | 2007-11-01 |
US20040028741A1 (en) | 2004-02-12 |
EP1327440A4 (de) | 2006-02-01 |
TWI289063B (en) | 2007-11-01 |
CA2824077A1 (en) | 2002-03-28 |
AU2001286237A1 (en) | 2002-04-02 |
US7727553B2 (en) | 2010-06-01 |
TW200524642A (en) | 2005-08-01 |
WO2002024166A1 (fr) | 2002-03-28 |
EP1974724A2 (de) | 2008-10-01 |
ATE431136T1 (de) | 2009-05-15 |
EP1327440A1 (de) | 2003-07-16 |
JP4868695B2 (ja) | 2012-02-01 |
ES2325764T3 (es) | 2009-09-16 |
CA2424001C (en) | 2013-10-22 |
EP1327440B1 (de) | 2009-05-13 |
JPWO2002024166A1 (ja) | 2004-01-29 |
CA2824077C (en) | 2016-01-26 |
CA2424001A1 (en) | 2003-03-20 |
DK1327440T3 (da) | 2009-06-08 |
DE60138722D1 (de) | 2009-06-25 |
EP1974724A3 (de) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1327440T5 (da) | Orale pr parater med gunstige nedbrydningsegenskaber | |
EP1884242A4 (de) | Pharmazeutische zusammensetzung | |
EE05022B1 (et) | Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat | |
DK200001170A (da) | Farmaceutiske sammensætninger | |
HUP9902808A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása | |
CA2395846A1 (en) | Diazepan derivatives or salts thereof | |
DE69908626D1 (de) | Orale kombination von lufenuron und nitenpyram gegen flöhe | |
RU96116411A (ru) | Быстро распадающаяся готовая препаративная форма трамадола или соли трамадола | |
US20050202083A1 (en) | Storage stable tablets of fosinopril sodium | |
DE60233552D1 (de) | Fenofibrattabletten | |
HUP0500842A2 (hu) | Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra | |
EP1645273A3 (de) | Neue Verwendung von (R)-(-)-2-(5-(4-Fluorophenyl)-3-Pyridylmethylaminomethyl)-Chromane und ihrer physiologisch verträglichen Salze | |
CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration | |
NO20033855L (no) | Fremgangsmåte ved fremstilling av farmasöytiske tabletter inneholdende paroxetinhydrokloridanhydrat | |
EP1113015A4 (de) | Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten | |
CA2443019A1 (en) | Kappa-opiate agonists for the treatment of bladder diseases | |
WO2008016165A3 (en) | Liquid preparation | |
WO2005034954A3 (en) | Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation | |
RU98114489A (ru) | СОСТАВ ИНГИБИТОРА 5α-РЕДУКТАЗЫ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ИСПОЛЬЗОВАНИЕ | |
NO20031030D0 (no) | Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel | |
TH45760B (th) | สารละลายพรูคาโลไพรด์สำหรับการให้ทางปาก | |
RU97119777A (ru) | Фармацевтическая таблетированная композиция противовоспалительного действия | |
WO2003004019A8 (en) | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia |